Docosahexaenoic acid in ARSACS: observations in two patients.

Abstract excerpt

BACKGROUND: Spastic ataxia of Charlevoix-Saguenay is a neurodegenerative condition due to mutations in the SACS gene and without a cure. Attempts to treatments are scarce and limited to symptomatic drugs. CASE PRESENTATION: Two siblings harboring biallelic variants in SACS underwent oral supplementation (600 mg/die) with docosahexaenoic acid (DHA), a well-tolerated dietary supplement currently used in SCA38...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Spinocerebellar Ataxias
• Share to Dietary Supplements
• Share to Disease Progression